HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by van Heeswijk, R. P. G. Articles by Cameron, D. W. Search for Related Content PubMed PubMed Citation Articles by van Heeswijk, R. P. G. Articles by Cameron, D. W. Social Bookmarking                         What's this?

Time-Dependent Interaction Between Lopinavir/Ritonavir and Fexofenadine

From the Ottawa Hospital, Division of Infectious Diseases (Dr van Heeswijk, Ms Seguin, Dr Cameron) and Department of Pharmacy (Dr van Heeswijk); The Ottawa Health Research Institute (Dr van Heeswijk, Mr Bourbeau, Ms Campbell, Dr Cameron); Ottawa Genome Center (Ms Campbell); University of Ottawa (Mr Chauhan, Dr Foster, Dr Cameron), Ottawa, Ontario, Canada.

This study investigated the effect of single-dose and steady-state lopinavir/ritonavir on the exposure to fexofenadine, as a measure of P-glycoprotein activity. Sixteen volunteers (8 women) received single-dose oral fexofenadine 120 mg alone, in combination with single-dose ritonavir 100 mg or lopinavir/ritonavir 400/100 mg (randomized 1:1, stratified by sex), and in combination with steady-state lopinavir/ritonavir 400/100 mg twice daily. Single-dose ritonavir and lopinavir/ritonavir increased the area under the fexofenadine plasma concentration-time curve from 0 to infinity (AUC) by 2.2- and 4.0-fold, respectively (P < .02). Steady-state lopinavir/ritonavir increased the fexofenadine AUC by 2.9-fold. No changes were observed in the fexofenadine elimination half-life (P > .12). The fexofenadine AUC was increased by lopinavir/ritonavir, likely due to increased bioavailability secondary to P-glycoprotein inhibition. After repeated administration of lopinavir/ritonavir, the interaction was attenuated compared to the single-dose effect, although a net inhibitory effect was maintained. Time-dependent inhibition of P-glycoprotein by lopinavir/ritonavir should be considered when P-glycoprotein substrates are coadministered.

Key Words: HIV • protease inhibitors • P-glycoprotein • lopinavir • fexofenadine

Address for reprints: Rolf P. G. van Heeswijk, PharmD, PhD, Tibotec BVBA, Gen De Wittelaan L11B3, 2800 Mechelen, Belgium; e-mail: rvheesw1{at}tibbe.jnj.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. M Foisy, E. M Yakiwchuk, and C. A Hughes Induction Effects of Ritonavir: Implications for Drug Interactions Ann. Pharmacother., July 1, 2008; 42(7): 1048 - 1059. [Abstract] [Full Text] [PDF]

				A. Gupta, G. M. Mugundu, P. B. Desai, K. E. Thummel, and J. D. Unadkat Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors Drug Metab. Dispos., June 1, 2008; 36(6): 1172 - 1180. [Abstract] [Full Text] [PDF]

				S. Matsushima, K. Maeda, N. Ishiguro, T. Igarashi, and Y. Sugiyama Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans Drug Metab. Dispos., April 1, 2008; 36(4): 663 - 669. [Abstract] [Full Text] [PDF]

				L. Tong, T. K. Phan, K. L. Robinson, D. Babusis, R. Strab, S. Bhoopathy, I. J. Hidalgo, G. R. Rhodes, and A. S. Ray Effects of Human Immunodeficiency Virus Protease Inhibitors on the Intestinal Absorption of Tenofovir Disoproxil Fumarate In Vitro Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3498 - 3504. [Abstract] [Full Text] [PDF]